Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
33.53 USD | -1.53% | -5.07% | +31.70% |
Financials (USD)
Sales 2024 * | 50.98M | Sales 2025 * | 70.78M | Capitalization | 2.09B |
---|---|---|---|---|---|
Net income 2024 * | -206M | Net income 2025 * | -240M | EV / Sales 2024 * | 33.5 x |
Net cash position 2024 * | 380M | Net cash position 2025 * | 373M | EV / Sales 2025 * | 24.3 x |
P/E ratio 2024 * |
-11.5
x | P/E ratio 2025 * |
-10.3
x | Employees | 186 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.75% |
Latest transcript on Kymera Therapeutics, Inc.
1 day | -1.53% | ||
1 week | -5.07% | ||
Current month | -0.27% | ||
1 month | +0.48% | ||
3 months | -22.47% | ||
6 months | +66.57% | ||
Current year | +31.70% |
Managers | Title | Age | Since |
---|---|---|---|
Nello Mainolfi
FOU | Founder | 45 | 15-08-31 |
Bruce Jacobs
DFI | Director of Finance/CFO | 54 | 19-07-14 |
Juliet Williams
CTO | Chief Tech/Sci/R&D Officer | - | 21-05-04 |
Members of the board | Title | Age | Since |
---|---|---|---|
Felix Baker
BRD | Director/Board Member | 55 | Mar. 27 |
Joanna Horobin
BRD | Director/Board Member | 69 | 18-04-30 |
John Maraganore
BRD | Director/Board Member | 60 | 22-01-16 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.10% | 0 M€ | 0.00% | - | |
0.09% | 0 M€ | 0.00% | - | |
0.05% | 1,487 M€ | +8.80% | - | |
0.04% | 2 M€ | -.--% |
Date | Price | Change | Volume |
---|---|---|---|
24-05-28 | 33.53 | -1.53% | 481,896 |
24-05-24 | 34.05 | -0.55% | 432,621 |
24-05-23 | 34.24 | -4.09% | 495,952 |
24-05-22 | 35.7 | +1.08% | 515,262 |
24-05-21 | 35.32 | -1.92% | 431,107 |
Delayed Quote Nasdaq, May 28, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+31.70% | 2.09B | |
+54.05% | 63.85B | |
-2.02% | 41.83B | |
+40.01% | 40.47B | |
-10.22% | 27.17B | |
+13.42% | 26.52B | |
-21.60% | 18.69B | |
+2.89% | 12.73B | |
+22.40% | 12.11B | |
+27.49% | 12.07B |
- Stock Market
- Equities
- KYMR Stock